# Krsnaa Diagnostics (NSE: KRSNAA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KRSNAA · Pivot · prices to 22 Oct 2026

Krsnaa Diagnostics (NSE: KRSNAA) closed at ₹510.75 on 22 Oct 2026, down 0.79% on the day. With a market capitalisation of ₹1,657 Cr, it ranks 1218th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 16.5× trailing earnings, against a return on equity of 10.3% in FY26. Over the past year the share price has fallen 38.5%. Its 52-week range is ₹504.00 (21 Oct 2026) to ₹838.00 (17 Nov 2025); the last close is 39.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹193 Cr (+3.5% year on year) and net profit ₹42 Cr (+101.7%), on a consolidated basis. Promoters held 27.11% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹510.75 |
| Market cap | ₹1,657 Cr |
| P/E (trailing) | 16.5 |
| ROE | 10.3% (FY26) |
| ROCE | 10.6% (FY26) |
| Debt to equity | 0.55 |
| 52-week high | ₹838.00 (17 Nov 2025) |
| 52-week low | ₹504.00 (21 Oct 2026) |
| 1-year return | −38.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹193 Cr | +3.5% | ₹42 Cr | +101.7% | ₹12.86 |
| Q3 FY26 | ₹181 Cr | +3.8% | ₹15 Cr | −21.1% | ₹4.72 |
| Q2 FY26 | ₹206 Cr | +10.5% | ₹24 Cr | +22.1% | ₹7.38 |
| Q1 FY26 | ₹193 Cr | +13.4% | ₹21 Cr | +14.5% | ₹6.35 |
| Q4 FY25 | ₹186 Cr | +11.9% | ₹21 Cr | +10.4% | ₹6.40 |
| Q3 FY25 | ₹175 Cr | +10.2% | ₹19 Cr | +49.7% | ₹6.01 |
| Q2 FY25 | ₹186 Cr | +19.9% | ₹20 Cr | +86.7% | ₹6.07 |
| Q1 FY25 | ₹170 Cr | +22.0% | ₹18 Cr | +22.4% | ₹5.55 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹717 Cr | ₹78 Cr |
| FY24 | ₹620 Cr | ₹57 Cr |
| FY23 | ₹487 Cr | ₹62 Cr |
| FY22 | ₹455 Cr | ₹68 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 27.11%
- Foreign institutions: 4.28%
- Domestic institutions: 14.51%
- Non-institutions: 54.09%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹885.70 | ₹1,828 Cr | 28.4 | — |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹26.21 | ₹1,715 Cr | 58.2 | — |
| [NGL Fine-Chem](https://app.pivotnow.in/stock/NGLFINE) | ₹2,717.20 | ₹1,679 Cr | 34.8 | — |
| [Jupiter Life Line Hospitals](https://app.pivotnow.in/stock/JLHL) | ₹244.75 | ₹1,605 Cr | 8.3 | — |
| [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹700.20 | ₹1,560 Cr | — | — |

## Questions and answers

### What is the share price of Krsnaa Diagnostics today?

Krsnaa Diagnostics (NSE: KRSNAA) last closed at ₹510.75 on 22 Oct 2026. Its 52-week high is ₹838.00 and its 52-week low is ₹504.00.

### What is the market cap of Krsnaa Diagnostics?

Krsnaa Diagnostics' market capitalisation is ₹1,657 Cr (₹1,657 Cr) at the 22 Oct 2026 close, ranking 1218th among the NSE companies Pivot tracks.

### What is the P/E ratio of Krsnaa Diagnostics?

Krsnaa Diagnostics trades at a trailing P/E of 16.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.8.

### What is the ROE and ROCE of Krsnaa Diagnostics?

Return on equity was 10.3% in FY26 and return on capital employed was 10.6% in FY26 (consolidated figures).

### Is Krsnaa Diagnostics a debt-free company?

No. Krsnaa Diagnostics' debt-to-equity ratio was 0.55 in FY26, with total debt of ₹468 Cr.

### What were Krsnaa Diagnostics' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Krsnaa Diagnostics reported revenue of ₹193 Cr, +3.5% year on year, and net profit of ₹42 Cr, +101.7% year on year.

### How has Krsnaa Diagnostics stock performed over the last year?

Krsnaa Diagnostics' share price has fallen 38.5% over the past year, −6.2% over three months and −7.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Krsnaa Diagnostics?

As of 30 Jun 2026: promoters 27.11%, foreign institutions 4.28%, domestic institutions 14.51%, non-institutions 54.09%.

### Who are Krsnaa Diagnostics' competitors?

The listed Pharma & Healthcare companies closest to Krsnaa Diagnostics by market cap are Windlas Biotech, Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem, Jupiter Life Line Hospitals and Astec LifeSciences.

### Is Krsnaa Diagnostics a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Krsnaa Diagnostics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KRSNAA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.